Sanofi-Aventis has not changed its offer of $69 per share for drugmaker Genzyme, a Sanofi spokesman said Monday, declining to comment on a report that the drugmaker had lined up more financing for its bid.
We have one offer at $69. No other offer has been made ... We would like to enter into a dialogue, said Sanofi spokesman Jean-Marc Podvin.
He declined to comment on a Wall Street Journal report released over the weekend that said Sanofi-Aventis had lined up more financing from Citigroup and Bank of America Corp.
Sanofi has said it already has financing from J.P. Morgan Chase & Co, BNP Paribas SA and Societe Generale SA.
The French drugmaker wants to reach a friendly agreement but has not ruled out a hostile offer made directly to Genzyme shareholders, sources previously told Reuters.
Last month, Genzyme rejected Sanofi's $69 per share offer as dramatically undervaluing the U.S. company and not a bid that justified entering merger talks.
Sources previously told Reuters that Genzyme sought an offer of at least $75 per share before Sanofi could review its books, while some investors want up to $80 a share in a deal. Sanofi wants to buy Genzyme, a leading maker of drugs for rare diseases, to fuel growth as some of its key treatments lose patent protection.